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Bicyclic peptides form one of the most promising platforms for drug development owing to their
biocompatibility, similarity and chemical diversity to proteins, and they are considered as a possible practical
tool in various therapeutic and diagnostic applications. Bicyclic peptides are known to have the capability of
being employed as an effective alternative to complex molecules, such as antibodies, or small molecules. This
review provides a summary of the recent progress on the types, synthesis and applications of bicyclic peptides.
More specifically, natural and synthetic bicyclic peptides are introduced with their different production methods
and relevant applications, including drug targeting, imaging and diagnosis. Their uses as antimicrobial agents, as
well as the therapeutic functions of different bicyclic peptides, are also discussed.

Introduction
Small chemical molecules with molecular weight (MW) <500 Da are the most usable FDA-approved drugs with
the ability to regulate a biological process. However, small molecules are generally limited to targeting proteins
with well-defined binding pockets (e.g., enzymes, receptors and ion channels). Small molecules cannot affect
proteins involved in protein–protein interactions (PPIs) because these proteins are not easily available. To
overcome the limitations of small molecules, many macromolecules with MW >5000 Da, such as antibodies,
have arrived in the clinic as therapeutics since the 1980s. These macromolecules can interact with challenging
targets but, unlike small molecules, they are too large to enter the cell and are thus limited to extracellular
targets [1]. Peptides, as the next-generation therapeutics, represent unique features – molecularly they are
between small molecules and macromolecules, but are biochemically and therapeutically distinct from both [2].
Peptides have a more specific function compared with small molecules. Therapeutic peptides are categorized as
linear or cyclic. Cyclic peptides do not have amino and carboxyl termini and are resistant
to hydrolysis by exopeptidases. Also, owing to the conformational rigidity, cyclic peptides usually have a better
biological activity compared with linear ones. The rigidity of cyclic peptides decreases the Gibbs free energy,
thus allowing the enhanced binding toward targets [3]. Cyclic peptides can be used as a therapeutic, drug
delivery tool, surfactant, imaging agent, biosensor or antimicrobial agent. Bicyclic peptides, compared with
monocyclic peptides, have additional advantages, including higher conformational rigidity, target binding
affinity and selectivity, improved metabolic stability and better membrane permeability [4].
Natural bicyclic peptides are produced by different organisms. Romidepsin, actinomycin D, moroidin and
celogentin C are some examples of natural bicyclic peptide that have different activities – like inhibition
of tubulin polymerization, prevention the polarization of actin filaments, inhibition of RNA polymerase II, among
others 4, 5, 6. Bicyclic peptide libraries include many bicyclic peptides with high diversity. Combinatorial
library technologies have recently been developed to rapidly synthesize and screen large bicyclic peptide
libraries for ligands against specific targets. Two categories can be mentioned for bicyclic peptide libraries:
biologic and synthetic. Some peptide libraries are restricted to peptidogenic amino acids, whereas other libraries
can contain nonpeptidogenic amino acids, such as β- or γ-amino acids, D-amino acids or non-natural amino
acids. Nowadays, different methods like phage display method, split-intein circular ligation of peptides and

proteins (SICLOPPS) and mRNA display are used for bicyclic peptide library fabrication [7]. In this review, we will
discuss types, preparation and application of bicyclic peptides as next-generation therapeutics.

Bicyclic peptide features and types
Bicyclic peptides are a class of polypeptides with two macrocyclic rings that have advantages over linear and
monocyclic peptides. Their size, structure, functionality and increased conformational rigidity improve their
proteolytic stability in the blood circulation, binding properties and offer better tissue penetration, widening
their application routes [1]. In addition, each ring in this bicyclic structure can function independently, allowing
these peptides to be bifunctional [8]. Bicyclic peptides potentially have some of the favorable properties
of monoclonal antibodies (high target specificity and affinity) and small molecules (stability and good tissue
penetration) and, therefore, might be appropriate candidates for the progress of therapeutics with low toxic
profiles against a diverse set of targets [9]. These molecules are classified into two groups: natural and synthetic.
There are different types of bicyclic peptides in nature, exhibiting various biological activities. Moroidin,
celogentins A–K, phallotoxins and amatoxins are typical examples of natural bicyclic peptides. Also, the various
activities of naturally occurring bicyclic peptides suggest that synthetic bicyclic peptides can mimic some
biological activities [1].

Natural bicyclic peptides

Many bicyclic peptides with various biological activities are naturally produced by different organisms (Table 1).
One of these naturally occurring peptides is romidepsin, which is extracted from the
bacterium Chromobacterium violaceum [10]. Because this bicyclic peptide inhibits histone deacetylase, it is used
as an anticancer agent in T cell lymphoma [11]. There is also a class of bicyclic heptapeptides consisting of at
least seven compounds (phalloidin, prophalloin, phalloin, phallisin, phallacidin, phallacin and phallisacin) isolated
from Amanita phalloides (the death cap mushroom) [12]. Phallotoxins bind actin, specifically at the interface
between F-actin subunits, and inhibit the depolarization of actin filaments 13, 14. Fluorescent derivatives
of phalloidin have mainly been used to localize and visualize actin filaments in cells [15]. Vitilevuamide, a
cytotoxic compound isolated from two marine ascidians, is a bicyclic 13-amino-acid peptide. This naturally
occurring bicyclic peptide is very toxic in mammalian cell lines and inhibits tubulin polymerization [5]. Owing to
the appealing features of bicyclic peptides, several strategies have been examined to generate synthetic bicyclic
peptides for various applications.
Table 1. Examples of naturally occurring bicyclic peptides
Name
Actinomycin D

Source
Streptomyces parvulus

Mechanism of action
Interfering with mRNA synthesis

Moroidin

Celosia argentea

Celogentin C

C. argentea

Phalloidin

Death cap mushroom
(Amanita phalloides)

Inhibitor of tubulin
polymerization
Inhibitor of tubulin
polymerization
Preventing the polarization of
actin filaments

α-Amanitin

A. phalloides

Theonellamide
F

Marine sponge
(Theonella)

Inhibition of RNA polymerases,
in particular RNA polymerase II
Inhibits growth of various
pathogenic fungi

Activity
An antineoplastic
antibiotic
Antimitotic activity

Refs
[6]

Antimitotic activity

[58]

Inhibition of
cytokinesis and
cytotaxis
Cytotoxicity

[15]

Cytotoxicity

[60]

[57]

[59]

Synthetic bicyclic peptides

The diverse biological functions of naturally occurring bicyclic peptides and their potential in the development of
novel therapeutics have encouraged scientists to generate synthetic bicyclic peptides with desired activities.
Consequently, the first synthetic bicyclic heptapeptide was synthesized in 1978, which was structurally similar to
phallotoxins 1, 16. Vancomycin, a branched tricyclic glycopeptide antibiotic, is produced by
the actinomycete Amycolaptosis orientalis and is commonly used for the treatment of serious bacterial
infections. Recently, Yang et al. reported a bicyclic tripeptide synthesis as a mimic of the ABC ring system of
vancomycin using the ruthenium-based cyclization chemistries [17]. In another study, Rodriguez and co-workers
designed and synthesized a polymyxin-based bicyclic peptide by developing a new solid-phase synthetic
approach and showed that this synthetic bicyclic peptide has the potential to be used as a source for the design
and generation of novel and more-effective carbohydrate receptors for bioanalytical or medicinal
applications [18].
Also, Dehua Pei and colleagues improved the cell permeability of protein tyrosine phosphatase 1B (PTP1B)
inhibitor 2 by a bicyclic system in which the cyclo(FΦRRRRQ) (cFΦR4, where Φ is L-naphthylalanine) as a novel
class of cell-penetrating peptide (CPP) is placed in one ring and the target-binding sequence constitutes the
other ring. Fusion of cyclic PTP1B inhibitor 2 with cFΦR4 as the cyclic cell-penetrating peptide produces bicyclic
peptides that are cell permeable and retain the ability to recognize specific intracellular targets [19].

Chemical methods for cyclization of peptides
To date, several strategies have been used to form synthetic bicyclic peptides. The first strategy was reported to
generate a bicyclic tryptathionine heptapeptide in 1978 by Zanotti et al. [16]. In this method, the first step
of cyclization involved formation of a thioether bond between a cysteine residue and a derivative of Ltryptophan, which was generated by oxidation with peroxyacetic acid. The second cyclization (head-to-tail
cyclization) was performed by the mixed anhydride method.
Kemp and McNamara described syntheses of the conformationally restricted cyclic nonapeptides cyclo-(Gly-LCys(Bzl)-Gly)3, cyclo-(L-Pr-GLy-L-Cys(Meb))3 and cyclo-(L-Cys(Meb)-LL-Acp)3, in which Meb = p-methoxybenzyl
and Acp = 3-amino-2-piperidone-6-carboxylic acid. In this method, a ring-forming reaction was performed by
1,3,5-tris(bromomethylene)benzene after removal of the S-blocking groups from each compound [20].
Sun et al. reported an efficient approach to synthesize amphipathic bicyclic peptides in 2001. The linear peptide
precursors were produced using the Boc/BOP protocol [21]. The sequences of these precursors contained an Nterminal cysteine, a C-terminal thioester and an internal cysteine residue. First, cyclization of unprotected
peptides was performed using an on-resin intramolecular thioester ligation reaction between N-terminal Cys
and C-terminal thioester (N-to-C cyclization). Finally, bicyclic peptides were obtained by forming an off-resin
intramolecular disulfide bond between N-terminal cysteine and an internal cysteine residue by DMSO oxidation
(Fig. 1a).

Figure 1. Various strategies for chemical synthesis of bicyclic peptides. (a) Synthesis through an on-resin
intramolecular thioester ligation and an off-resin DMSO-mediated disulfide formation. (b) Synthesis by ringclosing metathesis. (c) Synthesis by formation of C–C bond (through an intramolecular palladium-catalyzed C–H
activation process) between tryptophan and iodinated tyrosine or phenylalanine. (d) Synthesis through ringclosing alkyne metathesis. (e) Synthesis through the formation of an amide bond between the α- or γ-carboxyl
group of glutamate and the N terminus, then subjected to amide-bond formation conditions to perform the
second cyclization. Abbreviations: RCM, ring-close metathesis; RCAM, ring-close alkyne metathesis.
In another strategy, Ghalit et al. synthesized bicyclic mimics of the lantibiotic nisin by ring-closing metathesis. In
these alkene-/alkane-bridged bicyclic peptides, the disulfide bond and thioether bridge were replaced
with alkene staples (Fig. 1b) [22]. Later, Mendive-Tapia et al. reported a new stapling methodology for the
synthesis of peptides containing a C–C bond between tryptophan and phenylalanine or tyrosine residues via a
selective palladium-catalyzed C–H arylation process (Fig. 1c) [23]. Grandas and colleagues reported a
straightforward synthesis of bicyclic peptides from cysteine-containing peptides. In this approach, they formed
bicyclic peptides via an intramolecular Michael addition reaction between thiols and maleimides [24].
Also, Teixido et al. described solid‐phase synthesis and characterization of N‐methyl‐rich peptides. Synthesis of
high N‐methylamino acid content peptides is challenging because the coupling of protected N‐methylamino
acids with N‐methylamino acids generally occurs with low yields. They described (7‐azabenzotriazol‐1‐yloxy)‐
tris(pyrrolidino)phosphonium hexafluorophosphate (PyAOP) or PyBOP/1‐hydroxy‐7‐azabenzotriazole (HOAt) as
the most promising coupling reagents for these couplings. Also, they showed that the time of cleavage of the
peptide from the resin affected loss of Ac‐N‐methylamino acid when a peptide contains an acetylated N‐
methylamino acid at the N‐terminal position [25].
Bartoloni et al. showed that bicyclic homodetic peptides can be obtained by solid-phase peptide synthesis and
two subsequent cyclizations. The first on-resin cyclization was performed through the formation of
an amide bond between the α- or γ-carboxyl group of glutamate and the N terminus. The resulting monocyclic
peptides were then subjected to amide-bond formation conditions under high dilution to perform the second
cyclization and to form bicyclic peptides (Fig. 1e) [26]. This strategy was also used to prepare bridged bicyclic
peptides (BBPs) corresponding to the topology of bridged bicyclic alkanes, such as norbornane [27]. Recently, in
2016, Cromm and co-workers applied a chemically orthogonal ring-closing olefin (RCM) and alkyne metathesis
(RCAM) system to generate GTPase-targeting bicyclic peptides (Fig. 1d) [28]. In addition to the above methods, a
simple way to synthesize bicyclic peptides is the linking of two monocyclic peptides by different linkers. For

example, Oh et al. synthesized two different bicyclic peptides through linking monocyclic peptides
using triazole and β-alanine (β-Ala) linkers [29].

Screening of bicyclic peptides from a random library
A bicyclic peptide library contains a great number of bicyclic peptides and provides a powerful tool for the
isolation of bicyclic peptides against a target of interest for various applications. To build large libraries and
increase the chances of identifying bicyclic peptides with desired properties, various chemical and biological
methods have been developed.

Chemical methods

As mentioned in the previous section, the first chemically synthesized library of nine bicyclic peptides was
created by Sun et al. using intramolecular thioester ligation and DMSO-mediated disulfide formation [21]. To
synthesize larger libraries and increase the likelihood of finding peptides with desired properties, other methods
should be developed. The one-bead-two-compound (OBTC) approach is a simple method used to design bicyclic
libraries, in which each cyclic peptide is encoded on the same bead by the corresponding linear peptide [9].
One of the main advantages of chemical synthesis of bicyclic peptides is the possibility of the incorporation of
nonproteinogenic amino acids and nonpeptidic moeities into a peptide structure, which can increase the
diversity and stability of the peptide structure. Upadhyaya and co-workers devised an approach for generating
and screening large bicyclic peptide libraries displayed on rigid small-molecule scaffolds. Bicyclic peptides
produced by this method contained random residues of 24 different amino acids (including ten proteinogenic
amino acids, four nonproteinogenic α-L-amino acids and ten α-D-amino acids) in each ring. After screening of a
chemically synthesized library against tumor necrosis factor (TNF)α, they recognized an element that inhibits the
TNFα–TNFR interaction [9]. In another study, Upadhyaya et al. synthesized a bicyclic peptide library in OBTC
format according to the previous approach, screened against the K-Ras G12 V mutant and finally discovered
several direct Ras inhibitors [30].

Biological methods

Another method for producing bicyclic peptides is biological production through ribosomal synthesis, which can
generate large libraries with enormous diversity. Heinis et al. developed a phage strategy for generation of
combinatorial chemical bicyclic peptide libraries and affinity selection [31]. In this strategy, they constructed a
library of linear peptides using phage display. According to the phage display method, a library of peptides,
including two sequences of six random amino acids flanked by three cysteines [Cys-(Xaa)6-Cys-(Xaa)6-Cys], was
expressed on the surface of a filamentous phage. These linear phage-encoded peptides were tethered to the
trifunctional compound tris(bromomethyl)benzene (TBMB) in a nucleophilic substitution reaction that alkylated
the three Cys residues in the peptide sequences and converted the linear sequences into bicyclic peptides.
Finally, they isolated potent human plasma kallikrein inhibitors (Ki = 1.5 nM) from a library of >109 members [31].
In another study, Rebollo et al. produced bicyclic peptide phage libraries by combining dissimilar sized
macrocyclic rings (Fig. 2). They cloned 14 phage-coded peptide libraries of the format Cys(Xaa)m-Cys-(Xaa)n-Cys,
wherein Xaa are random amino acids and the numbers ‘m’ and ‘n’ were 3, 4, 5 or 6. The libraries were exposed
to three rounds of affinity assortments against the cancer-associated protease uPA [32]. The phage display
bicyclic peptide can also be generated through the formation of two disulfide bonds [33] but, in peptides with
several cysteine residues, disulfide isomerization can lead to multiple peptides with various biological actions.
Chen et al. developed a dithiol amino acid (Dtaa) that can make two disulfide bridges at a single amino acid site
and showed that substitution of two cysteines by Dtaas can prevent the formation of different disulfide
bond isomers [34].

Figure 2. Construction of a phage-encoded peptide library of the format CXC(X)5C(X)5C. The CXC motif can direct
the folding of randomized peptides on the phage surface toward either a fused or bridged bicyclic structure.
After iterative affinity selections, the selected peptide sequence can then be structurally reshaped into a specific
bicyclic structure (either fused or bridged) through orthogonal Cys–Pen disulfide pairing technology (only two of
the four Pen-substituted analogs were present) [35].
Very recently, Zheng et al. presented the de novo design of cysteine–penicillamine (Cys–Pen)-mixed peptide
scaffolds, which can be folded into specific isomers [35]. The resulting sequence-independent peptide scaffolds,
which were constrained with two noncanonical disulfide bonds, were isomerically pure and topologically
formidable. Another phage-screening strategy for developing bicyclic peptides was reported by Zha et al., in
which a phage-encoded peptide library of the format CXC(X)5C(X)5C was synthesized. The CXC motif can direct
the folding of phage-displayed peptides toward either a fused or bridged bicyclic structure. Finally, the selected
peptide sequences were structurally reshaped into bicyclic structures using orthogonal Cys–Pen disulfide pairing
technology. They obtained a library of 4.5 × 109 independent transformants by transformation of
the phagemid vector into Escherichia coli [36]. This strategy can be useful to develop bicyclic peptide ligands
(Fig. 2).
Another display technique used for biological production of bicyclic peptides is mRNA display. In this cell-free
technique, a covalent bond between each protein or peptide and its own encoding mRNA is formed
using puromycin as a mimic of aminoacyl tRNA [37]. The mRNA–protein complex is reverse transcribed to cDNA
and employed for in vitro selection. The DNA sequences encoding selected peptides can be analyzed by
sequencing [38]. Sako et al. developed a novel approach to construct bicyclic peptide scaffolds by modification
of the mRNA display method. They reprogrammed the genetic code to construct a peptide scaffold containing a
cysteine (Cys) at the N terminus and three nonproteinogenic amino acids [4-(2-chloroacetyl) aminobutyric
acid (Cab), Aha, azidohomoalanine (Aha) and Propargylglycine (Pgl)]. Post-translational cyclizations performed
by crosslinking between two pairs of amino acids, Cys–Cab and Aha–Pgl [39]. In a method recently described by
Hacker et al., two orthogonal cyclization steps (bisbromomethylbenzene cysteine alkylation and coppermediated azide–alkyne cyclo addition) were used to make highly constrained bicyclic peptide libraries. In this
strategy, the attachment points for each loop are independent, thereby enabling the formation of either
manacle or theta-bridged bicyclic peptides, and in vitro selection of bicyclic peptides with desired characteristics
can be done using mRNA display (Fig. 3) [40]. SICLOPPS is a split-intein-based technique for the intracellular
construction of cyclic peptides [41]. The method of Bionda and Fasan: ribosomal production of bicyclic peptides
in E. coli, involved the SICLOPPS method (for initial N-to-C circularization) combined with genetic incorporation

of O-(2-bromoethyl)-tyrosine (O2beY) (for an inter-side-chain thioether bond-forming reaction between a
cysteine residue and O2beY to form the bicyclic peptide) (Fig. 4) [42].

Figure 3. mRNA display scheme. Comparative in vitro selections against streptavidin. PURE translation is started
with puromycin-linked mRNA. mRNA–peptide fusions are bis-alkylated with α,α′-dibromo-m-xylene (green box)
and immobilized on oligo (dT) resin to form the monocyclic peptides. The monocyclic fusion pool is split
after reverse transcription and bound to nickel resin, where the CuAAC reaction is performed on the portion of
the pool targeted for bicyclic peptide formation (blue box). The monocyclic and bicyclic fusion pools are then
used to select for high-affinity binders to streptavidin. Following competitive elution with biotin, functional
fusions were amplified via PCR to generate the enriched round 2 DNA library. All steps were performed
independently for subsequent rounds [39].

Figure 4. The approach to ribosomal synthesis of thioether-bridged bicyclic peptides in Escherichia coli. From N
to C, the linear precursor polypeptide includes the split intein DnaE C-terminal domain (IntC), a Ser or Cys
residue at IntC++1 site, the unnatural amino acid O-(2-bromoethyl)-tyrosine (O2beY or ‘Z’), a variable target
sequence comprising the reactive cysteine and a DnaE N-terminal domain attached to a chitin-binding domain
(IntN–CBD). The two intended paths to make the bicyclic product are indicated [41].

Applications of bicyclic peptides in medicine
Diverse biological activities of naturally occurring bicyclic peptides have inspired scientists to identify and
synthesize new bicyclic peptides for various applications, such as therapeutic agents, drug targeting, imaging
and diagnostics.

Therapeutic agents
Enzyme inhibitors

Some bicyclic peptides can act as enzyme inhibitors and be used as therapeutic agents in many diseases. For
example, Jaulent and Leatherbarrow designed two potent bicyclic protease inhibitors by combining two
advantageous features of two naturally occurring inhibitors: Bowman Birk inhibitor (BBI) and sunflower trypsin
inhibitor (SFTI)-1. The resulting bicyclic and bifunctional protease inhibitors showed the potent inhibitory
properties of the parent structures that are also relatively resistant to proteolysis; but they cannot inhibit
two proteases at the same time [43].

In another study, two bicyclic peptide inhibitors of the serine protease urokinase-type plasminogen
activator (uPA) were designed rationally by conversion of an established monocyclic peptide (upain-2) to bicyclic
peptides. The affinities of two bicyclic peptide inhibitors were similar to upain-2, and isothermal
titration calorimetry (ITC) data indicated that the bicyclic peptides reduced loss of entropy upon binding to
uPA [44]. Islam et al. synthesized bicyclic tetrapeptide histone deacetylase (HDAC) inhibitors by designing and
synthesizing CHAP31-based bicyclic tetrapeptide hydroxamic acids by altering the aliphatic loop length. The
potent HDAC inhibitory activity of these nonaromatic bicyclic HDAC inhibitors was evaluated and confirmed in
vivo and in vitro [45]. More recently, Teufel et al. discovered stable and long-lasting bicyclic peptide inhibitors
against plasma kallikrein (PKal) using a combination of phage display and chemical cyclization. The efficacy of
these peptides in inhibition of PKal activity was confirmed by different in vitro assays and in different biological
matrices and demonstrated that bicyclic constrained peptides act as potent and highly specific PKal inhibitors
that can be useful in the treatment of diabetic retinopathy and diabetic macular edema (DME) [46].

PPI inhibitors

Targeting and inhibition of PPIs has appeared as a novel approach for discovering and developing new
therapeutics for complex and multifactorial diseases. Therefore, one of the main goals of developing bicyclic
peptides is the development of inhibitors against PPIs; and, in this regard, several bicyclic peptide PPI inhibitors
have been synthesized. For example, Grb2, a signaling adaptor, has a key role in receptor tyrosine
kinase signaling pathways, and Grb2 inhibitors could be useful as anticancer drugs. A bicyclic peptide inhibitor of
the SH2 domain of Grb2 was synthesized by conversion of a monocyclic peptide into bicyclic peptide, enhancing
its potency and selectivity for Grb2 SH2 [8].
In another study, Lian et al. identified a bicyclic peptide inhibitor of the TNFα–TNFR interaction by screening of
large combinatorial libraries of bicyclic peptides. The resulting bicyclic peptide PPI inhibitor can protect from cell
death induced by TNFα [9]. In a recent study, Guardiola et al. designed metabolically stable bicyclic peptides
targeting the epidermal growth factor (EGF)–EGFR interaction. EGF contributes to tumor progression and
performs its function by binding to its receptor (EGFR), which initiates intracellular events leading to tumor
development. A series of bicyclic-constrained peptides mimicking one of the interacting domains of EGFR was
designed using a combination of in silico and biophysical methods. The inhibitory effect of these peptides on the
EGF–EGFR interaction was established in a specific PPI-disruption assay [47]. These peptides also selectively
decrease the viability of human cancer cells expressing a high level of EGFR, with mid-micromolar
IC50 values [47]. The efficacy of these peptides, in addition to their metabolic stability, makes them suitable as
complementary therapeutics in cancer therapy.

Receptor agonist and antagonist

Some bicyclic peptides act as agonists or antagonists for cell surface receptors, which are either naturally
occurring or rationally designed (Fig. 5a). For example, BI-32169 is a naturally occurring bicyclic 19-peptide
isolated from Streptomyces sp. (DSM 14996) and is a potent human glucagon receptor antagonist [48]. Jia et al.
developed a specific bicyclic peptide antagonist (EG3287) of vascular endothelial growth factor (VEGF)-A165
binding to neuropilin (NP)-1, which is a receptor for VEGF in endothelial cells. By characterization of this
antagonist, they reported that the exon 8 of VEGF is very important for NP-1 binding, and NP-1 is needed for
optimum kinase insert domain receptor (KDR) signaling [49].

Figure 5. Applications of bicyclic peptides in medicine.

Drug targeting

Bicyclic peptides can be ideal candidates for drug targeting owing to their small size and their ability to bind to
different protein targets with good affinity and specificity (Fig. 5b). Moreover, they also exhibit better
proteolytic stability and improved plasma stability compared with linear peptides 50, 51. Paclitaxel (PTX), a
mitotic inhibitor, binds to tubulin and prevents the disassembly of microtubules and is used as a microtubulestabilizing drug in cancer treatment. Chen et al. conjugated paclitaxel with a bicyclic peptide E[c(RGDyK)]2 (RGD)
and evaluated its antitumor activity in a metastatic breast cancer cell line [52]. Because RGD peptide can
selectively bind to αv integrin receptors, conjugation of PTX to RGD allowed its targeted delivery to tumor cells
expressing αvβ3 integrin. Bicycle Therapeutics (Cambridge, MA) developed the bicyclic peptide platform based
on bicyclic-peptide–drug conjugates (BDCs) for cell-specific targeting of chemotherapeutic agents. BT1718 is a
Bicycle drug conjugate developed by Bicycle Therapeutics to target tumors [53]. BT1718 binds selectively to
membrane type 1 matrix metalloprotease (MT1-MMP) with high affinity and is a promising compound to
treat solid tumors. MT1-MMP is a tumor-associated membrane-anchored endopeptidase overexpressed in a
variety of cancer cells. The results of recent studies show that BDCs can be developed as alternatives
to antibody–drug conjugates and a superior strategy for targeted drug delivery [53].

Imaging and diagnosis (PET scan imaging)

Bicyclic peptides can develop into diagnostic imaging agents, especially as positron emission tomography (PET)
tracers (Fig. 5c). The main advantages of bicyclic peptides over other protein binders (particularly monoclonal
antibodies) are their faster clearance from the blood circulation owing to their smaller sizes, resulting in shorter
imaging times delay, and better signal-to-noise ratio (SNR) [1]. Park et al. synthetized two bicyclic RGD peptides:
c(RGD-ACP-K) and c(RGD-ACH-K), by incorporating aminocyclopentane (ACP) or aminocyclohexane (ACH) into a
monocyclic RGD peptide. After conjugation to DOTA and radiolabeling with radiometal 64Cu, the efficiency of
these peptides as PET radiotracers was evaluated for cancer imaging. Both bicyclic peptides and their DOTA
conjugates exhibited high affinities toward U87MG glioblastoma cells, which are better than the monocyclic
c(RGDyK). The corresponding 64Cu complexes showed excellent stability in human and mouse serum and high
tumor uptake, as observed by PET, which demonstrated their promise as PET radiotracers for tumor
imaging [54]. In another example, Eder et al. identified a bicyclic peptide targeting MT1-MMP (tumoroverexpressed matrix metalloproteinase) with subnanomolar affinity and showed the power of its
radioconjugation as a tumor-targeting probe in an HT1080 xenograft mouse model. In vivo studies using
different mouse xenograft models showed high affinity to MT1-MMP (Kd at ˜1 nM) and, compared to
radiolabeled antibodies directed against the same target, showed rapid tumor penetration characteristics and
high potency and chemical versatility [55].

As antimicrobial agents

Di Bonaventura et al. discovered that antimicrobial bridged bicyclic peptides (AMBPs) were active
against Pseudomonas aeruginosa and its biofilm. Screening of all AMBPs for antibiofilm activity led to the

identification of two potent P. aeruginosa biofilm inhibitors that were enhancers of the activity of polymyxin.
They used the concept of chemical space to discover their AMBPs and calculated their chemical space using 2DP
– a 136-dimensional molecular fingerprint for peptides. These results suggest that bridged bicyclic peptides can
be useful as a new class of antimicrobial peptides [56]. In a recent study, this group identified an antimicrobial
bicyclic peptide with potent activity against several multidrug-resistant Gram-negative bacteria. They explored a
virtual bicyclic peptide library using the concept of chemical space [57].

Concluding remarks
Bicyclic peptides (with two macrocyclic rings) have advantages over linear and monocyclic peptides owing to
their size, structure, functionality and increased conformational rigidity. This class of polypeptides has some of
the favorable properties of monoclonal antibodies and small molecules and, therefore, can have different
therapeutic and diagnostic applications. Various chemical, biological and combinatorial methods have been
developed to synthesize large bicyclic peptide libraries and increase the chances of identifying peptides with
desired properties. Owing to the similarity of antibodies and peptides in the affinity and specificity to various
proteins, it is anticipated that, in the future, peptides will play an important part as therapeutics, diagnostics
agents and research tools rather than antibodies, because they have a less complex structure, greater metabolic
stability and lower cost of production.
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